#BIO22: By the Numbers: After the music died, you can see some encouraging signs on the M&A and licensing fronts. But where's the big buy-in?
It’s clear from #ASCO22 that biopharma audiences are back, live, at the big conferences. That’s encouraging, as we return to more face-to-face meetings to advance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.